Comparative Pharmacology
Head-to-head clinical analysis: V CILLIN versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: V CILLIN versus VEETIDS 500.
V-CILLIN vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic